Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-BN measles vaccine
- Development stage
- Unknown
- Lead developer
- Bavarian Nordic
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MVA-BN measles vaccine is a recombinant, non-replicating viral vector vaccine candidate developed by Bavarian Nordic. It utilizes the Modified Vaccinia Ankara (MVA-BN) platform, a highly attenuated strain of vaccinia virus that is unable to replicate in human cells, to deliver and express the hemagglutinin (H) and fusion (F) glycoproteins of the measles virus. This platform is designed to induce both robust neutralizing antibody responses and potent T-cell mediated immunity. The primary indication for this vaccine is the prevention of measles, particularly in populations where traditional live-attenuated vaccines, such as the standard Measles-Mumps-Rubella (MMR) vaccine, are contraindicated. This includes immunocompromised individuals, such as those with HIV, and infants who may still possess maternal antibodies that interfere with live-attenuated vaccine efficacy. The MVA-BN vector itself acts as an endogenous adjuvant by stimulating innate immune pathways, including TLR2 and TLR6.
- Other names
- Modified Vaccinia Ankara-Bavarian Nordic measles vaccinerMVA-BN-Measlesrecombinant MVA-BN measles vaccine
02
Targets
MV-H (Measles virus hemagglutinin protein)F (Coagulation factors)
Beyond the preview
Go deeper on MVA-BN measles vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-BN measles vaccine.